These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 16160612

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
    Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertens Res; 2008 Jun; 31(6):1199-208. PubMed ID: 18716369
    [Abstract] [Full Text] [Related]

  • 4. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
    Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators.
    Circulation; 2004 Aug 31; 110(9):1103-7. PubMed ID: 15313950
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.
    Lee TM, Lin MS, Chou TF, Chang NC.
    Am J Physiol Heart Circ Physiol; 2006 Sep 31; 291(3):H1281-9. PubMed ID: 16565312
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.
    Mizukawa M, Ohmori K, Obayashi A, Ishihara Y, Yoshida J, Noma T, Yukiiri K, Kosaka H, Kohno M.
    Hypertens Res; 2009 Jul 31; 32(7):617-24. PubMed ID: 19461650
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet.
    Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M.
    J Hypertens; 2005 Oct 31; 23(10):1879-86. PubMed ID: 16148612
    [Abstract] [Full Text] [Related]

  • 11. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
    Takai S, Miyazaki M.
    Am J Cardiovasc Drugs; 2006 Oct 31; 6(6):363-6. PubMed ID: 17192125
    [Abstract] [Full Text] [Related]

  • 12. AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.
    Rodríguez-Iturbe B, Sato T, Quiroz Y, Vaziri ND.
    Kidney Int; 2004 Aug 31; 66(2):668-75. PubMed ID: 15253721
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist in apolipoprotein E-deficient mice.
    Kato M, Sada T, Chuma H, Mizuno M, Terashima H, Fukushima Y, Koike H.
    J Cardiovasc Pharmacol; 2006 Jun 31; 47(6):764-9. PubMed ID: 16810077
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits.
    Shiomi M, Ito T.
    Metabolism; 1994 May 31; 43(5):559-64. PubMed ID: 8177044
    [Abstract] [Full Text] [Related]

  • 17. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits.
    Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, Fukami M, Fukushige J, Hosokawa T, Tamura A.
    Arterioscler Thromb Vasc Biol; 1995 Nov 31; 15(11):1938-44. PubMed ID: 7583574
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
    Mizuno M, Sada T, Kato M, Fukushima Y, Terashima H, Koike H.
    J Cardiovasc Pharmacol; 2006 Oct 31; 48(4):135-42. PubMed ID: 17086090
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.